United States· US:0002-2980_94e137ac-9f6b-4904-8999-3e55603a2407
RETEVMO
A selpercatinib product containing selpercatinib, registered in United States by Eli Lilly and Company. The same ATC class is registered in 15 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Selpercatinib is registered in 15 of 19 countries.
Countries holding a registration under ATC L01EX22 (selpercatinib), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 9 of them publish a price we can compare per daily dose
Selpercatinib · ATC L01EX22
15 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of selpercatinib costs, country by country.
Normalised to the WHO defined daily dose (0.32 g), the median price runs from $69.21 in France to $270.60 in Switzerland — a ×3.9 gap.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Selpercatinib · price per daily dose (0.32 g)
USD · FX 28 Sept 2026
- CH Switzerland$270.60
- FR France$69.21
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- SELPERCATINIB
- Manufacturer
- Eli Lilly and Company
- Country
- United States (US)
- ATC code
- L01EX22
- ATC class
- Selpercatinib
- Defined daily dose
- 0.32 g, O
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- July 19, 2026
Packs & prices · 4
- ndc110002298026120 CAPSULE in 1 BOTTLE (0002-2980-26)
- ndc11000229806060 CAPSULE in 1 BOTTLE (0002-2980-60)
- ndc110002-2980-26
- ndc110002-2980-60
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
356 interactions on record for selpercatinib.
Graded by severity as the source publishes them — 166 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Selpercatinib · interactions on record
356 records
- 166 severe
- 180 moderate
- 10 minor
Most severe, free to view
- Magnesium carbonateA02AA01severe
- Magnesium oxideA02AA02severe
- Magnesium hydroxideA02AA04severe
- Kombinationen von AluminiumsalzenA02AB10severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Selpercatinib in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaRETSEVMOEli Lilly Nederland B.V., Utrecht
- FinlandRetsevmoEli Lilly Nederland B.V
- SwitzerlandRetsevmo 80 mg, gélulesEli Lilly (Suisse) SA
- SpainRETSEVMO 80 mg CAPSULAS DURASEli Lilly Nederland B.V.
- IcelandRetsevmoEli Lilly Nederland B.V.*
- NetherlandsRetsevmo 80 mg harde capsulesEli Lilly Nederland B.V.
- PolandRetsevmoEli Lilly Nederland B.V.
- SwedenRetsevmo 80 mg Kapsel, hårdEli Lilly Nederland B.V.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Retsevmo
- Liechtenstein · Retsevmo
- Norway · Retsevmo
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/75ab4927-e852-4578-8b34-d625f770261e GET /v1/drugs/75ab4927-e852-4578-8b34-d625f770261e?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "ORAL",
"source": "ndc",
"strength": "80",
"substance": "SELPERCATINIB",
"productndc": "0002-2980",
"dosage_form": "CAPSULE",
"dea_schedule": null,
"strength_unit": "mg/1",
"application_number": "NDA213246",
"marketing_category": "NDA"
}See everything about selpercatinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.